Información del artículo
Resumen
Los marcadores tumorales son, en general, proteínas que se asocian a enfermedades malignas. Pueden detectarse en sangre periférica y son útiles para el cribado, el diagnóstico, la estadificación, el pronóstico y el seguimiento de estas enfermedades. También pueden servir para detectar la presencia de metástasis ocultas, monitorizar la respuesta al tratamiento y descubrir recurrencias
En el presente artículo se exponen los principales marcadores tumorales serológicos usados en cirugía hepatobiliopancreática. La alfafetoproteína es el marcador más útil en el hepatocarcinoma, especialmente para el diagnóstico y la detección de las recurrencias tras el tratamiento. El antígeno carcinoembrionario será util en los casos de metástasis hepáticas de cáncer colorrectal. El CA 19.9 puede ayudar en el diagnóstico diferencial de las tumoraciones pancreáticas. El antígeno carcinoembrionario, el CA 19.9 y el CA 125 pueden ser útiles en casos de tumores de las vías biliares
Palabras clave:
Marcadores tumorales
Alfafetoproteína
Antígeno carcinoembrionario
CA 19
9
Tumor markers are usually proteins associated with malignancy. They can be detected in peripheral blood and can be used for the screening, diagnosis, staging, prognosis, and follow-up of malignant diseases. Markers may also be used to detect the presence of occult metastatic disease, to monitor response to treatment, or to detect recurrent disease
The present article describes the main serum tumor markers used in hepatobiliopancreatic surgery. Alpha-fetoprotein (AFP) is the most useful marker for hepatocellular carcinoma, particularly for the diagnosis and detection of recurrence after treatment. Carcinoembryonic antigen (CEA) is used to detect hepatic metastases from colorectal cancer. CA 19.9 can be helpful in establishing the differential diagnosis of pancreatic masses. CEA, CA 19.9 and CA 125 can be useful in biliary tract tumors
Key words:
Tumor markers
Alfa-fetoprotein
CEA
CA 19
9
El Texto completo está disponible en PDF
Bibliografía
[1.]
G.D. Zuidema, C.J. Yeo, M.B. Orringer, R. Heitmiller, D.T. Dempsey, J.G. Turcotte, et al.
WB Saunders, (2002),
[2.]
A.S. Befeler, A.M. Di Bisceglie.
Hepatocellular carcinoma: diagnosis and treatment.
Gastroenterology, 122 (2002), pp. 1609-1619
[3.]
G.D. Zuidema, C.J. Yeo, M.B. Orringer, R. Heitmiller, D.T. Dempsey, J.G. Turcotte, et al.
WB Saunders, (2002),
[4.]
J.A. Marrero, G.L. Su, W. Wei, D. Emick, H.S. Conjeevaram, R.J. Fontana, et al.
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Hepatology, 37 (2003), pp. 1114-1121
[5.]
F. Nomura, K. Ohrishi, I. Tanabe.
Clinical features and prognosis of hepatocellular carcinoma with reference to serum alfa-fetoprotein levels.
Cancer, 64 (1989), pp. 1700-1707
[6.]
G. Torzilli, M. Makuuchi, A. Ferrero, T. Takayama, A.M. Hui, H. Abe, et al.
Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
Hepatogastroenterology, 49 (2002), pp. 740-745
[7.]
L.X. Qin, Z.Y. Tang.
The prognostic significance of clinical and pathological features in hepatocellular carcinoma.
World J Gastroenterol, 8 (2002), pp. 193-199
[8.]
K. Taketa, S. Okada, N. Win, K.M. Wind.
Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar.
Acta Med Okayama, 56 (2002), pp. 317-320
[9.]
M. Soresi, C. Magliarisi, P. Campagna, G. Leto, G. Bonfissuto, A. Riili, et al.
Uselfunesss of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.
Anticancer Res, 23 (2003), pp. 1747-1753
[10.]
G.D. Zuidema, C.J. Yeo, M.B. Orringer, R. Heitmiller, D.T. Dempsey, J.G. Turcotte, et al.
WB Saunders, (2002),
[11.]
T. Koh, H. Taniguchi, H. Katoh, S. Kunishima, A. Yamaguchi, H. Yamagis.
Are both PIVKA and alpha-fetoprotein necessary in follow management after hepatic resection for hepatocellular carcinoma?.
Hepatogastroenterology, 49 (2002), pp. 1615-1618
[12.]
T. Sonoyama, T. Oxhiai, T. Hironaka, H. Yamagishi.
Predictors of postoperative diffuse intrahepatic recurrence of hepatocellular carcinoma.
Hepatogastroenterology, 50 (2003), pp. 1078-1084
[13.]
Y.F. Jiang, Z.H. Yang, J.Q. Hu.
Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy.
World J Gastroenterol, 6 (2000), pp. 61-65
[14.]
M. Matsumura, Y. Shiratori, Y. Niwa, T. Tanaka, K. Ogura, T. Okudaira, et al.
Presence of alpha-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma.
J Hepatol, 31 (1999), pp. 332-339
[15.]
N. Okuda, A. Nakao, S. Takeda, K. Oshima, N. Kanazumi, T. Nonami, et al.
Clinical significance of alpha-fetoprotein mRNA during perioperative period in HCC.
Hepatogastroenterology, 46 (1999), pp. 381-386
[16.]
H. Okuda, T. Nakanishi, K. Takatsu, A. Saito, N. Hayashi, M. Yamamoto, et al.
Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
J Gastroenterol Hepatol, 17 (2002), pp. 772-778
[17.]
T.C. Poon, T.S. Mok, A.T. Chan, C.M. Chan, V. Leong, S.H. Tsui, et al.
Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with non diagnostic serum total alpha-fetoprotein.
Clin Chem, 48 (2002), pp. 1021-1027
[18.]
W.J. Tao, S.T. Wang, N.H. Chow, T.T. Chang, P.W. Lin, D.G. Tu.
Serum tissue polypeptide specific antigen as a noninvasive prognostic indicator for early recurrence of hepatocellular carcinoma after curative resection.
Cancer, 95 (2002), pp. 112-118
[19.]
T. Koh, H. Taniguchi, H. Katoh, S. Kunishima, A. Yamaguchi, H. Yamagishi.
Are both PIVKA-II and alpha-fetoprotein necessary in follow-up management after hepatic resection for hepatocellular carcinoma?.
Hepatogastroenterology, 49 (2002), pp. 1615-1618
[20.]
M. Gotoh, T. Nakatani, T. Masuda, Y. Mizuguchi, M. Sakamoto, R. Tsuchi, et al.
Prediction of invasive activities in hepatocellular carcinoma with special reference to alpha-fetoprotein and des-gamma carboxyprotrombin.
Jpn J Clin Oncol, 33 (2003), pp. 522
[21.]
R.Z. Ni, J.F. Huang, M.B. Xiao, M. Li, X.Y. Meng.
Glycilproline dipeptidul aminopeptidase isoenzyme in diagnosis of primary hepatocellular carcinoma.
World J Gastroenterol, 9 (2003), pp. 710-713
[22.]
N. Miura, G. Shiota, T. Nakagawa, Y. Maeda, A. Sano, A. Marumoto, et al.
Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patientes with hepatocellular carcinoma.
Oncology, 64 (2003), pp. 430-434
[23.]
J.S. Wagner, M.A. Adson, J.A. Van Heerden, M.H. Adson, D.M. Ilstrup.
The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment.
Ann Surg, 199 (1984), pp. 502-508
[24.]
D.B. Goodman.
The use of carcinoembryonic antigen as a tumor marker.
Am Ass Clin Chem, ENDO In-Service Training and Continuing Education, 9 (1991), pp. 5-17
[25.]
H.J. Wanebo, B. Rao, C.M. Pinsky, R.G. Hoffman, M. Stearns, M.K. Schwartz, et al.
The use of preoperative carcinoembryonic antigen level as a prognostic indicator to complement pathological staging.
N Engl J Med, 299 (1978), pp. 448-451
[26.]
G. Slater, A.E. Papatestas, A.H. Aufses.
Preoperative carcinoembryonic antigen levels in colorectal carcinoma.
Arch Surg, 114 (1979), pp. 52-53
[27.]
P. Thomas, C.A. Toth, K.S. Saini, J.M. Jessup, G. Steele.
The structure, metabolism and function of the carcinoembryonic antigen gene family.
Biochim Biophys Acta, 1032 (1990), pp. 177-189
[28.]
H. Ueno, H. Mochizuki, K. Hatsuse, K. Hase, T. Yamamoto.
Indicators for treatment strategies of colorectal liver metastases.
Ann Surg, 231 (2000), pp. 59-66
[29.]
M. Cromheecke, K.P. De Jong, H.J. Hoekstra.
Current treatment for colorectal cancer metastatic to the liver.
Eur J Surg Oncol, 25 (1999), pp. 451-463
[30.]
N. Pietra, L. Sarli, R. Costi, C. Ouchemi, M. Grattarola, A. Peracchia.
Role of follow-up in management of local recurrence of colorectal cancer. A prospective randomized study.
Dis Colon Rectum, 41 (1998), pp. 1127-1133
[31.]
C. Glover, P. Douse, P. Kane, J. Karani, H. Meire, S. Mohammadtaghi, et al.
Accuracy of investigations for asymptomatic colorectal liver metastases.
Dis Colon Rectum, 45 (2002), pp. 476-484
[32.]
S. Takahashi, K. Inoue, M. Konishi, T. Nakagouri, T. Kinoshita.
Prognostic factors for poor survival after repeat hepatectomy in patients with colorectal liver metastases.
Surgery, 133 (2003), pp. 627-634
[33.]
M.J. Duffy.
Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?.
Clin Chem, 47 (2001), pp. 624
[34.]
Anónimo.
Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer.
J Clin Oncol, 14 (1996), pp. 2843-2877
[35.]
J.K. Seifert, T. Junginger.
Prognostic factors for cryotherapy of colorectal liver metastases.
Eur J Surg Oncol, 30 (2004), pp. 34-40
[36.]
A.D. Polichronidis, A.K. Tsaroucha, S.K. Anadnostoulis, E.E. Efstathiou, P.G. Georgiadis, C.E. Somopoulos.
Serum levels of c-erbB-2 correlate with advanced stage and liver metastasis in colorectal cancer.
Folia Med, 45 (2003), pp. 12-16
[37.]
M.R. Posner, R.J. Mayer.
The use of serologic tumor markers in gastrointestinal malignancies.
Hematol Oncol Clin North Am, 8 (1994), pp. 533-552
[38.]
D.K. Pleskow, H.J. Berger, J. Gyves, E. Allen, A. McLean, D.K. Podolsky.
Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer.
Ann Intern Med, 110 (1989), pp. 704-709
[39.]
K. Sakamoto, Y. Haga, R. Yoshimura, H. Egami, Y. Yokoyama, M. Akagi.
Comparative effectiveness of the tumor diagnostics, CA 19-9, CA 125, and carcinoembryonic antigen in patients with diseases of the digestive system.
Gut, 28 (1987), pp. 323-329
[40.]
F. Safi, H.G. Berger, R. Bittner, M. Büchler, W. Krautzberger.
CA19.9 and pancreatic adenocarcinoma.
Cancer, 57 (1986), pp. 779-783
[41.]
Y. Hamanaka, S. Hamanaka, M. Suzuki.
Sialyl Lewis(a) ganglioside in pancreatic cancer tissue correlates with the serum CA 19-9 level.
Pancreas, 13 (1996), pp. 160-165
[42.]
D.V. Mann, R. Edwards, S. Ho, W.Y. Lau, G. Glazer.
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Eur J Surg Oncol, 26 (2000), pp. 474-479
[43.]
R.E. Ritts, H.A. Pitt.
CA19-9 in pancreatic cancer.
Surg Oncol Clin N Am, 7 (1998), pp. 93-101
[44.]
F. Safi, W. Schlosser, S. Falkenreck, H.G. Beger.
CA 19-9 serum course and prognosis of pancreatic cancer.
Int J Pancreatol, 20 (1996), pp. 155-161
[45.]
American Gastroenterological Association. Technical review on the epidemiology, diagnosis and treatment of pancreatic ductal adenocarcinoma.
Gastroenterology, 117 (1999), pp. 1464-1484
[46.]
C.E. Forsmark, L. Lambiase, S.B. Vogel.
Diagnosis of pancreatic cancer and prediction of unresecability using the tumor-associated antigen CA19-9.
Pancreas, 9 (1994), pp. 731-734
[47.]
F. Safi, W. Schlosser, S. Falkenreck, H.G. Beger.
Prognostic value of CA19-9 serum course in pancreatic cancer.
Hepatogastroenterology, 45 (1998), pp. 253-259
[48.]
M.B. Albert, W.M. Steinberg, J.P. Henry.
Elevated serum levels of tumor marker CA19-9 in acute cholangitis.
Dig Dis Sci, 33 (1988), pp. 1223-1225
[49.]
G. Galizia, E. Lieto, F. Ferraraccio, P. Castellano, F. De Vita, M. Orditura, et al.
A true splenic cyst producing carbohydrate antigen 19-9 and cancer antigens 50 and 125, but not interleukin 10.
Dig Surg, 20 (2003), pp. 71-74
[50.]
R.N. Holtzman, A.D. Heymann, F. Bordone, G. Marinoni, P. Barillari, S.J. Wahl.
Carbohydrate antigen 19-9 and carcinoembryonic antigen immunostaining in benign multicystic mesothelioma of the peritoneum.
Arch Pathol Lab Med, 125 (2001), pp. 944-947
[51.]
E.M. Yoshida, C.H. Scudamore, S.R. Erb, D.A. Owen, H.K. Silver.
Markedly elevated serum CA 19-9 levels in a case of chronic pancreatitis.
Can J Surg, 38 (1995), pp. 83-86
[52.]
F. Safi, F.S. Roscher, R. Bittner, B. Schenkluhn, H.P. Dopfer, H.G. Beger.
High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis: serological and immunohistochemical findings.
Pancreas, 2 (1987), pp. 398-403
[53.]
D.Q. Mu, G.F. Wang, S.Y. Peng.
p53 protein expression and CA 19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis.
World J Gastroenterol, 9 (2003), pp. 1815-1818
[54.]
K. Nishida, T. Kaneko, M. Yoneda, S. Nakagawa, T. Ishikawa, E. Yamane, et al.
Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis.
J Surg Oncol, 71 (1999), pp. 140-146
[55.]
H. Takamori, T. Hiraoka, T. Yamamoto.
Expression of tumor-associated carbohydrate antigens correlates with hepatic metastasis of pancreatic cancer: clinical and experimental studies.
Hepatogastroenterology, 43 (1996), pp. 748-755
[56.]
W.M. Steinberg, R. Gelfand, K.K. Anderson, J. Glenn, S.H. Kurtzman, W.F. Sindelar, et al.
Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas.
Gastroenterology, 90 (1986), pp. 343-349
[57.]
M.G. Schlieman, H.S. Ho, R.J. Bold.
Utility of tumor markers in determining resectability of pancreatic cancer.
Arch Surg, 138 (2003), pp. 951-956
[58.]
J. Glenn, W.M. Steinberg, S.H. Kurtzman, S.M. Steinberg, W.F. Sindelar.
Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas.
J Clin Oncol, 6 (1988), pp. 462-468
[59.]
H. Ishii, S. Okada, T. Sato, H. Wakasugi, H. Saisho, J. Furese, et al.
CA19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer.
Hepatogastroenterology, 44 (1997), pp. 279-283
[60.]
U. Halm, T. Schumann, I. Schiefke, H. Witzigmann, J. Mossner, V. Keim.
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
Br J Cancer, 82 (2000), pp. 1013-1016
[61.]
C.G. Willett, W.J. Daly, A.L. Warshaw.
CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer.
Am J Surg, 172 (1996), pp. 350-352
[62.]
K. Ohara, H. Tatsuzaki, N.G. Molotkova, T. Oda, K. Yuzawa, Y. Saida, et al.
Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer.
Hepatogastroenterology, 48 (2001), pp. 859-863
[63.]
T. Okusaka, S. Okada, T. Sato, H. Wakasugi, H. Saisho, J. Furuse, et al.
Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.
Hepatogastroenterology, 45 (1998), pp. 867-872
[64.]
O. Micke, F. Bruns, U. Schafer, R. Kurowski, E. Horst, N. Willich.
CA 19- 9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy.
Anticancer Res, 23 (2003), pp. 835-840
[65.]
O. Micke, F. Bruns, R. Kurowski, E. Horst, A.F. DeVries, J.W. Hausler, et al.
Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
Int J Radiat Oncol Biol Phys, 57 (2003), pp. 90-97
[66.]
Y. Shibamoto, T. Manabe, G. Ohshio, K. Sasai, Y. Nishimura, M. Imamura, et al.
High-dose intraoperative radiotherapy for unresectable pancreatic cancer.
Int J Radiat Oncol Biol Phys, 34 (1996), pp. 57-63
[67.]
Pancreatic Adenocarcinoma Practice Guidelines in Oncology – v.1.2002. National Comprehensive Cancer Network. Comprehensive Cancer Network®
[68.]
M. Takeuchi, S. Kondo, H. Sugiura, H. Katoh.
Pre-operative predictors of short-term survival after pancreatic cancer resection.
Hepatogastroenterology, 45 (1998), pp. 2399-2403
[69.]
A. Andicoechea, F. Vizoso, E. Alexandre, A. Martínez, M. Cruz Díez, L. Riera, et al.
Comparative study of carbohydrate antigen 195 and carcinoembryonic antigen for the diagnosis of pancreatic carcinoma.
World J Surg, 23 (1999), pp. 227-231
[70.]
J.Y. Yiannakou, P. Newland, F. Calder, A.N. Kingsnorth, J.M. Rhodes.
Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. CAM17.1/WGA mucin assay for the serological diagnosis of pancreatic cancer.
Lancet, 349 (1997), pp. 389-392
[71.]
F. Gansauge, S. Gansauge, N. Parker, M.I. Beger, B. Poch, K.H. Link, et al.
CAM 17.1-a new diagnostic marker in pancreatic cancer.
Br J Cancer, 74 (1996), pp. 1997-2002
[72.]
K. Satake, Y.S. Chung, K. Umeyama, T. Takeuchi, Y.S. Kim.
The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumors markers. A retrospective study.
Cancer, 68 (1991), pp. 149-152
[73.]
A. Frena.
Span-1 and exocrine pancreatic carcinoma. The clinical role of a new tumor marker.
Int J Biol Markers, 16 (2001), pp. 189-197
[74.]
M. Carpela-Holmstrom, J. Louhimo, U.H. Stenman, H. Alfthan, C. Haglund.
CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Anticancer Res, 22 (2002), pp. 2311-2316
[75.]
M. Ventrucci, G.M. Ubalducci, A. Cipolla, M.A. Panella, A. Ligabue.
Serum CA 242: the search for a valid marker of pancreatic cancer.
Clin Chem Lab Med, 36 (1998), pp. 179-184
[76.]
P.A. Pasanen, M. Eskelinen, K. Partanen, P. Pikkarainen, I. Penttila, E. Alhava.
A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Br J Cancer, 69 (1994), pp. 562-565
[77.]
H. Suwa, G. Ohshio, N. Okada, Z. Wang, M. Fukumoto, T. Imamura, et al.
Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.
Gut, 40 (1997), pp. 647-653
[78.]
A. Nanashima, H. Yamaguchi, T. Nakagoe, S. Matsuo, Y. Sumida, T. Tsuji, et al.
High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas.
J Hepatobiliary Pancreat Surg, 6 (1999), pp. 391-395
[79.]
X.Y. Zhao, S.Y. Yu, S.P. Da, L. Bai, X.Z. Guo, X.J. Dai, et al.
A clinical evaluation of serological diagnosis for pancreatic cancer.
World J Gastroenterol, 4 (1998), pp. 147-149
[80.]
M. Manzanera, C. Jiménez, E. Moreno, C. Moreno, D. Rodríguez, P. Rico.
Tratamiento del colangiocarcinoma hiliar.
Cir Esp, 69 (2001), pp. 159-168
[81.]
A. Leong, R. Sormunen, W. Tsui, C.T. Liew.
HEP PAR 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumors and metastatic carcinoma.
Histopathology, 33 (1998), pp. 318-324
[82.]
N. Kawahara, M. Ono, K. Taguchi, M. Okamoto, M. Shimada, K. Takeneka, et al.
Enhanced expression of trombospondin-1 and hypovascularity in human cholangiocarcinoma.
Hepatology, 28 (1998), pp. 1512-1517
[83.]
K. Ashida, T. Terada, Y. Kitamura, N. Kaibara.
Expression of E-caderin, alpha-catenin, beta-catenin and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study.
Hepatology, 27 (1998), pp. 974-982
[84.]
P.C. De Groen, G.J. Gores, N.F. LaRusso, L.L. Gunderson, D.M. Nagorney.
Biliary tract cancers.
N Engl J Med, 341 (1999), pp. 1368-1379
[85.]
J.K. Ramage, A. Donaghy, J.M. Farrant, R. Iorns, R. Williams.
Serum tumors markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.
Gastroenterology, 108 (1995), pp. 865-869
[86.]
A.H. Patel, D.M. Harnois, G.G. Klee, N.F. LaRusso, G.J. Gores.
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
Am J Gastroenterol, 95 (2000), pp. 204-207
[87.]
R. Hultcrantz, R. Olsson, A. Danielsson, G. Jarnerot, L. Loof, B.O. Ryden, et al.
A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
J Hepatol, 30 (1999), pp. 669-673
[88.]
H.A. Pitt, A. Nakeeb, R.A. Abrams, J. Coleman, S. Piantadosi, C.J. Yeo, et al.
Perihiliar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.
Ann Surg, 221 (1995), pp. 788
[89.]
A. Nakeeb, P.A. Lipsett, K.D. Lillemoe, M.K. Fox-Talbot, J. Coleman, J.L. Cameron, et al.
Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
J Surg Oncol, 171 (1996), pp. 147
[90.]
R.E. Ritts, D.M. Nagorney, D.J. Jacobson, R.W. Talbot, V.R. Jr. Zurawski.
Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.
Pancreas, 9 (1999), pp. 707-716
[91.]
J.A. Thomas, M.W. Scriven, M.C. Puntis, B. Jasani, G.T. Williams.
Elevated serum CA 19-9 levels in hepatobiliary cystadenoms with mesenchymal stroma. Two case report with immunohistochemical confirmation.
Cancer, 70 (1992), pp. 1841-1846
[92.]
C.P. Ramírez, M.A. Suárez, J. Santoyo, J.L. Fernández, M. Jiménez, J.A. Pérez, et al.
Actualización del diagnóstico y el tratamiento del cáncer de vesícula biliar.
Cir Esp, 71 (2002), pp. 102-111
[93.]
B.L. Strom, G. Maislin, S.L. West, B. Atkinson, M. Herlyn, S. Saul, et al.
Serum CEA and CA19-9: potential future diagnostic or screening tests for gallbladder cancer?.
Int J Cancer, 45 (1990), pp. 821-824
Copyright © 2004. Asociación Española de Cirujanos
